OPKO HEALTH, INC. OPK
We are a diversified healthcare company that seeks to establish industry-leading positions in large and rapidly growing medical markets. Our pharmaceutical business features NGENLA® (somatrogon-ghla), also referred to as Somatrogon (hGH-CTP), a once-weekly human growth hormone injection. We have partnered with Pfizer Inc. ("Pfizer") for further development and commercialization of Somatrogon (hGH-CTP). Regulatory approvals for Somatrogon (hGH-CTP) for the treatment of children and adolescents as young as three years of age with growth disturbance due to insufficient secretion of growth hormone, have been secured in more than 50 markets worldwide, including in the United States, European Union Member States, Japan, Canada, and Australia under the brand name NGENLA®.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $606.9M | $713.1M | $863.5M | $1.00B | $1.77B | $1.44B | $901.9M | $990.3M | $966.0M | $1.12B |
| Cost of revenue | $400.9M | $494.6M | $545.4M | $716.0M | — | — | — | — | $559.0M | $564.1M |
| Gross profit | $205.9M | $218.5M | $318.1M | $288.2M | — | — | — | — | $407.1M | $553.4M |
| R&D | $124.0M | $105.2M | $89.6M | $73.9M | $76.8M | $75.3M | $117.9M | $125.6M | $126.4M | $113.9M |
| SG&A | $223.0M | $304.2M | $300.6M | $372.7M | $468.9M | $355.6M | $343.3M | $358.3M | $414.6M | $407.3M |
| Total operating expenses | $724.3M | $865.2M | $1.02B | $1.23B | $1.76B | $1.38B | $1.18B | $1.16B | $1.24B | $1.21B |
| Operating income | -$117.4M | -$152.1M | -$157.0M | -$226.3M | $18.8M | $57.7M | -$274.1M | -$171.2M | -$276.4M | -$96.6M |
| Interest expense | $0 | $47.5M | $13.5M | $12.1M | $18.9M | — | — | — | — | — |
| Pre-tax income | -$241.4M | -$10.4M | -$184.3M | -$391.5M | -$14.0M | $48.7M | -$305.0M | -$177.3M | -$271.9M | -$96.8M |
| Income tax | $15.7M | $42.8M | $4.4M | $63.5M | $15.5M | $17.6M | $7.1M | $38.7M | $18.9M | $56.1M |
| Net income | -$225.68B | -$53.22B | -$188.86B | -$328.40B | -$30.14B | $30.6M | -$314.9M | -$153.0M | -$305.2M | -$48.4M |
| EPS, basic | -0.30 | -0.08 | -0.25 | -0.46 | -0.05 | 0.05 | -0.53 | -0.27 | -0.55 | -0.09 |
| EPS, diluted | -0.30 | -0.08 | -0.25 | -0.46 | -0.05 | 0.05 | -0.53 | -0.27 | -0.55 | -0.10 |
| Shares, diluted (wtd. avg.) | $751.1M | $694.0M | $751.8M | $719.1M | $648.1M | $640.7M | $595.5M | $563.1M | $559.2M | $555.6M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $364.4M | $426.6M | $95.9M | $153.2M | $134.7M | $72.2M | $85.5M | $96.5M | $91.5M | $168.7M |
| Receivables | $90.3M | $118.0M | $123.4M | $127.3M | $259.6M | $286.3M | $134.6M | $143.9M | $165.5M | $220.3M |
| Inventory | $65.8M | $56.8M | $65.7M | $74.1M | $86.5M | $132.3M | $53.4M | $42.3M | $49.3M | $47.2M |
| Total current assets | $581.9M | $662.1M | $309.5M | $394.5M | $823.0M | $523.2M | $324.0M | $317.7M | $348.9M | $483.6M |
| Property, plant and equipment | $73.9M | $70.1M | $75.4M | $82.9M | — | — | — | $144.7M | $146.6M | $122.8M |
| Goodwill | $484.3M | $529.3M | $598.3M | $595.9M | $520.6M | $718.6M | $710.0M | $712.0M | $717.1M | $704.6M |
| Other intangibles | $516.3M | $616.6M | $740.3M | $823.5M | $321.7M | $475.0M | $529.0M | $614.5M | $683.8M | $764.0M |
| Total assets | $1.93B | $2.20B | $2.01B | $2.17B | $2.40B | $2.47B | $2.31B | $2.45B | $2.59B | $2.77B |
| Accounts payable | $41.1M | $47.1M | $69.7M | $67.0M | $82.0M | $100.9M | $62.5M | $47.4M | $74.3M | $53.4M |
| Short-term debt | $344.0M | $437.2M | $2.0M | $1.7M | — | — | — | $5.9M | $11.9M | $12.0M |
| Total current liabilities | $146.7M | $193.1M | $200.1M | $213.5M | $330.0M | $375.5M | $249.1M | $288.3M | $312.0M | $263.3M |
| Long-term debt | $2.3M | $3.0M | $50.6K | $9.3M | $205.3M | $251.2M | $270.3M | $4.7M | $1.6M | $717.0K |
| Total liabilities | $664.0M | $834.8M | $622.5M | $605.6M | $714.6M | $801.5M | $694.5M | $659.8M | $746.3M | $674.8M |
| Retained earnings | -$2.29B | -$2.07B | -$2.01B | -$1.82B | -$1.51B | -$1.48B | -$1.51B | -$1.20B | -$1.05B | -$730.0M |
| Total equity | $1.27B | $1.37B | $1.39B | $1.56B | $1.69B | $1.67B | $1.61B | $1.79B | $1.84B | $2.05B |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$178.5M | -$183.5M | -$28.2M | -$95.2M | $38.3M | $39.5M | -$172.5M | -$109.1M | -$92.1M | $32.0M |
| Depreciation and amortisation | $91.6M | $98.2M | $105.3M | $108.7M | $78.7M | $85.4M | $93.8M | $97.3M | $102.1M | $96.6M |
| Stock-based compensation | $10.7M | $11.0M | $11.4M | $18.5M | $13.6M | $8.9M | $13.4M | $21.8M | $28.3M | $42.7M |
| Capital expenditure | $12.3M | $25.0M | $16.3M | $24.6M | $32.2M | $33.7M | $12.7M | $27.9M | $46.5M | $18.5M |
| Investing cash flow | $230.3M | $352.2M | -$18.2M | $91.0M | $35.9M | -$18.3M | -$13.3M | -$26.1M | -$46.7M | -$20.7M |
| Financing cash flow | -$118.1M | $184.2M | -$11.3M | $23.0M | -$10.3M | -$35.1M | $175.2M | $140.9M | $61.0M | -$35.2M |
| Buybacks | $47.0M | $90.2M | $0 | $0 | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-197120.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |